Serum microRNA profiles as prognostic biomarkers for HBV-positive hepatocellular carcinoma
Metrics: PDF 1452 views | HTML 1632 views | ?
Hao-Tu Zhu1,*, Abdulbaqi M. E. Hasan1,*, Rong-Bin Liu1, Zi-Chen Zhang1, Xiao Zhang1, Jing Wang1, Hai-Yun Wang1, Fang Wang1, Jian-Yong Shao1
1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, and Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China
*These authors contributed equally to this work
Jian-Yong Shao, email: firstname.lastname@example.org
Keywords: serum microRNA, biomarkers, hepatocellular carcinoma, prognosis, deep sequencing
Received: January 28, 2016 Accepted: May 28, 2016 Published: June 15, 2016
To establish serum microRNA profiles as prognostic biomarkers in hepatocellular carcinoma patients (HCCs), we used deep sequencing to screen serum microRNAs in a discovery set .Twelve up-regulated serum miRNAs were selected for qPCR analysis in a training set. MiR-192-5p and miR-29a-3p were identified and associated with HCC prognosis. HCCs with high concentrations of miR-192-5p and miR-29a-3p had poorer overall survival (OS) and progression-free survival (PFS) than those with low concentrations. We calculated a prognostic index (PI) score and classified patients into low-, medium- and high-risk groups. OS and PFS among the 3 groups from the training set were significantly different (all P < 0.05). PI (PIOS, PIPFS) score was the only independent prognostic predictor for OS and PFS of HCCs in the training set. These results were further confirmed in a validation set. In conclusion, differentially expressed serum miRNAs can be helpful for predicting survival in HCCs.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.